{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:25:12Z","timestamp":1758050712651,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1016\/j.cellimm.2011.10.002","type":"journal-article","created":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T14:51:03Z","timestamp":1318690263000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advantage of higher-avidity CTL specific for Tax against human T-lymphotropic virus-1 infected cells and tumors"],"prefix":"10.1016","volume":"272","author":[{"given":"Takako","family":"Kitazono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuetsu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2011.10.002_b0005","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","article-title":"Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera","volume":"78","author":"Hinuma","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2011.10.002_b0010","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1073\/pnas.81.8.2534","article-title":"Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease","volume":"81","author":"Yoshida","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2011.10.002_b0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2011.10.002_b0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2011.10.002_b0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13550280152403272","article-title":"HTLV-I proviral load correlates with progression of motor disability in HAM\/TSP: analysis of 239 HAM\/TSP patients including 64 patients followed up for 10years","volume":"7","author":"Matsuzaki","year":"2001","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.272.5258.74","article-title":"Population dynamics of immune responses to persistent viruses","volume":"272","author":"Nowak","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2011.10.002_b0035","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.4049\/jimmunol.173.8.5121","article-title":"The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1","volume":"173","author":"Vine","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0040","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.133.2.1037","article-title":"Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia\/lymphoma patient","volume":"133","author":"Kannagi","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.leu.2403176","article-title":"Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia\/lymphoma","volume":"18","author":"Arnulf","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2011.10.002_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/348245a0","article-title":"Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease","volume":"348","author":"Jacobson","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2011.10.002_b0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/intimm\/3.8.761","article-title":"Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells","volume":"3","author":"Kannagi","year":"1991","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1359-6101(00)00028-9","article-title":"Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B","volume":"12","author":"Jeang","year":"2001","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cellimm.2011.10.002_b0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.immunol.19.1.475","article-title":"Multiple viral strategies of HTLV-1 for dysregulation of cell growth control","volume":"19","author":"Yoshida","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ijc.2910540411","article-title":"Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukemia cells","volume":"54","author":"Kannagi","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellimm.2011.10.002_b0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1385\/IR:31:1:13","article-title":"High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors","volume":"31","author":"Alexander-Miller","year":"2005","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2011.10.002_b0080","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4049\/jimmunol.166.3.1690","article-title":"High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL","volume":"166","author":"Derby","year":"2001","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cellimm.2011.10.002_b0085","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.4049\/jimmunol.0900069","article-title":"The avidity and lytic efficiency of the CTL response to HTLV-1","volume":"182","author":"Kattan","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0090","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.187.10.1647-b","article-title":"Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides","volume":"187","author":"Gallimore","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2011.10.002_b0095","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.4049\/jimmunol.167.5.2577","article-title":"Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8ab versus CD8aa expression","volume":"167","author":"Cawthon","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0100","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.171.10.4974","article-title":"Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC\/anti-CD28-coated microspheres","volume":"171","author":"Walter","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4049\/jimmunol.170.1.174","article-title":"High avidity CD8+ T cells are the initial population elicited following viral infection of the respiratory tract","volume":"170","author":"Gray","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0110","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.4049\/jimmunol.156.7.2473","article-title":"Importance of MHC class 1 a2 and a3 domains in the recognition of self and non-self MHC molecules","volume":"156","author":"Newberg","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0115","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0145-2126(91)90031-N","article-title":"IL-2-dependent ATL cell lines with phenotypes differing from the original leukemia cells","volume":"15","author":"Yamada","year":"1991","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cellimm.2011.10.002_b0120","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.189.7.1063","article-title":"Fas gene mutation in the progression of adult T cell leukemia","volume":"189","author":"Maeda","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2011.10.002_b0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jneuroim.2004.10.007","article-title":"Involvement of p38 MAPK signaling pathway in IFN-g and HTLV-I expression in patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"159","author":"Fukushima","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","article-title":"HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from b2 microglobulin (b2m) HLA-A2.1 monochain transgenic H-2Db b2m double knockout mice","volume":"185","author":"Pascolo","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2011.10.002_b0135","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4049\/jimmunol.171.5.2548","article-title":"Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen","volume":"171","author":"Okazaki","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0140","doi-asserted-by":"crossref","first-page":"10645","DOI":"10.1128\/JVI.01351-05","article-title":"Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice","volume":"80","author":"Okazaki","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0145","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.intimp.2009.06.006","article-title":"Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II","volume":"9","author":"Maeda","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1620\/tjem.157.1","article-title":"Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I","volume":"157","author":"Lee","year":"1989","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.cellimm.2011.10.002_b0155","doi-asserted-by":"crossref","first-page":"e6517","DOI":"10.1371\/journal.pone.0006517","article-title":"Abnormally high levels of virus-infected IFN-g+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder","volume":"4","author":"Yamano","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cellimm.2011.10.002_b0160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/326881a0","article-title":"Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2","volume":"326","author":"Gotch","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2011.10.002_b0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4049\/jimmunol.149.1.136","article-title":"Species specificity in the interaction of CD8 with the a3 domain of MHC class I molecules","volume":"149","author":"Newberg","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0170","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1073\/pnas.93.9.4102","article-title":"Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy","volume":"93","author":"Alexander-Miller","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2011.10.002_b0175","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1128\/JVI.74.13.5769-5775.2000","article-title":"In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity","volume":"74","author":"Sedlik","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0180","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254\u2013262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2011.10.002_b0185","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.162.4.2227","article-title":"Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers","volume":"162","author":"Yee","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0190","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.162.2.989","article-title":"High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy","volume":"162","author":"Zeh","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0195","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/eji.200939451","article-title":"CTL quality and the control of human retroviral infections","volume":"39","author":"Bangham","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0200","first-page":"273","article-title":"Defective human T-cell leukemia virus in adult T-cell leukemia patients","volume":"2","author":"Konishi","year":"1984","journal-title":"Mol. Biol. Med."},{"key":"10.1016\/j.cellimm.2011.10.002_b0205","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.86.14.5620","article-title":"Detection of mRNA for the tax1\/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction","volume":"86","author":"Kinoshita","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2011.10.002_b0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev.immunol.15.1.15","article-title":"Human T cell leukemia virus type I (HTLV-I) and human diseases","volume":"15","author":"Uchiyama","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0215","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.4049\/jimmunol.171.10.5116","article-title":"High avidity antigen-specific CTL identified by CD8-independent tetramer staining","volume":"171","author":"Choi","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0220","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/jvi.66.5.2928-2933.1992","article-title":"Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells","volume":"66","author":"Kannagi","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2011.10.002_b0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molmed.2009.12.004","article-title":"T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing","volume":"16","author":"Govers","year":"2010","journal-title":"Trends Mol. Med."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874911002590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874911002590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:46:45Z","timestamp":1757803605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874911002590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"alternative-id":["S0008874911002590"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2011.10.002","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantage of higher-avidity CTL specific for Tax against human T-lymphotropic virus-1 infected cells and tumors","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2011.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}